Author

Nathalie Pello-Leprince-Ringuet

Observed names: N. Pello-Leprince-Ringuet, Nathalie Pello Leprince Ringuet, Nathalie Pello Leprince-Ringuet, Nathalie Pello‐Leprince‐Ringuet, Pello-Leprince-Ringuet, Nathalie

Observed institution: Ipsen (France)

ORCID: 0009-0005-6843-925X

Observed ORCID: 0009-0005-6843-925X

OpenAlex ID: A5057866798

EQUINOXE study: Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin‐releasing hormone agonist for prostate cancer

2021 · Stéphane Droupy, Marie‐Hélène Colson, et al. · BJUI Compass · 4

PDF

Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy

2018 · Thierry Lebret, Alain Ruffion, et al. · Therapeutic Advances in Urology · 4

PDF

2024 · François Rozet, Christophe Hennequin, et al. · The Aging Male · 2

PDF

Baseline parameters of patients with prostate cancer (PCa) initiating a triptorelin treatment for at least 12 months in real life, TALISMAN study interim analysis.

2022 · Antoine Thiery-Vuillemin, Jerome Rigaud, et al. · Journal of Clinical Oncology · 2

PO-1479 Management of androgen deprivation therapy (ADT) by French radiation oncologists, TALISMAN study

2023 · G. Crehange, T. Lebret, et al. · Radiotherapy and Oncology · 1

Main reasons of choice of formulation and route of triptorelin treatment initiated in patients with prostate cancer (PCa): TALISMAN study.

2023 · Antoine Thiery-Vuillemin, Gilles Crehange, et al. · Journal of Clinical Oncology · 1

PD-0417 Planned total duration of triptorelin treatment in patients with prostate cancer, TALISMAN study

2022 · G. Crehange, T. Lebret, et al. · Radiotherapy and Oncology · 1

Quality of life of partners of patients treated with gonadotropin-releasing hormone (GnRH) agonist for prostate cancer: Final analysis of the EQUINOXE study, focusing on relation between quality of life and dyadic adjustment

2019 · A. Descazeaud, M.H. Colson, et al. · European Urology Supplements · 1

855 Pooled analysis of observational studies in prostate cancer: quality of life changes in 1723 patients, 6 months after initiation of triptorelin

2026 · Igor Latorzeff, Pierre Mongiat-Artus, et al. · Radiotherapy and Oncology

1917 Changes in health-related quality of life in patients with prostate cancer initiating triptorelin: focus on age groups

2026 · Igor Latorzeff, Stéphane Droupy, et al. · Radiotherapy and Oncology

Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study

2025 · Thierry Lebret, Gilles Crehange, et al. · Therapeutic Advances in Urology

1701: Compliance to a 1-year triptorelin treatment in real life, TALISMAN final analysis (NCT04593420)

2024 · Gilles Créhange, Jérôme Rigaud, et al. · Radiotherapy and Oncology

Quality of life of prostate cancer (PCa) patients aged 60 years and older: Changes in QLQ-ELD14 dimensions after a six-month gonadotropin-releasing hormone agonist (GnRHa) therapy, according to age groups–Primary analysis of PRISME study.

2021 · Francois Rozet, Christophe Hennequin, et al. · Journal of Clinical Oncology

Treatment of aggressive prostate cancers in real life: Initiation, schedule, and management of triptorelin treatment (TALISMAN)—Design of the study.

2021 · Thierry Lebret, Jerome Rigaud, et al. · Journal of Clinical Oncology

Cognitive status of prostate cancer (PCa) patients aged 60 years and older after a six-month gonadotropin-releasing hormone agonist (GnRHa) therapy, according to age groups: Secondary analysis of PRISME study.

2021 · Morgan Roupret, Francois Rozet, et al. · Journal of Clinical Oncology

Visual analogue scales (VAS) as exploratory evaluation of eight dimensions in prostate cancer (PCa) patients aged 60 years and older initiating a gonadotropin-releasing hormone agonist (GnRHa) therapy: Secondary analysis of PRISME study.

2021 · Christophe Hennequin, Pierre Mongiat-Artus, et al. · Journal of Clinical Oncology

Quality of life of prostate cancer (PCa) patients with testosterone deficiency symptoms (TDS) before initiation of gonadotropin-releasing hormone (GnRH) agonist therapy, subgroup analysis of EQUINOXE study

2020 · A. Descazeaud, M.H. Colson, et al. · European Urology Open Science

Pd10-07 Quality of Life of Prostate Cancer (pca) Patients With Testosterone Deficiency Symptoms (tds) Before Initiation of Gonadotropin-releasing Hormone (gnrh) Agonist Therapy, Subgroup Analysis of Equinoxe Study

2020 · Stephane Droupy*, Marie-Helene Colson, et al. · The Journal of Urology

Mental perception of prostate cancer (PCa) disease in patients aged 60 years and older initiating gonadotropin-releasing hormone agonist (GnRHa) therapy.

2020 · Christophe Hennequin, Francois Rozet, et al. · Journal of Clinical Oncology

Quality of life of prostate cancer (PCa) patients with testosterone deficiency symptoms (TDS) before initiation of gonadotropin-releasing hormone (GnRH) agonist therapy: Subgroup analysis of EQUINOXE study.

2020 · Stephane Droupy, Marie-Helene Colson, et al. · Journal of Clinical Oncology

Cognitive status of prostate cancer (PCa) patients aged 60 years and older initiating gonadotropin-releasing hormone agonist (GnRHa) therapy, by age group.

2020 · Francois Rozet, Christophe Hennequin, et al. · Journal of Clinical Oncology

Mp22-13 Impact of Relational Cohesion and Sexuality on the Quality of Life of Patients Treated With Gonadotropin-releasing Hormone (gnrh) Agonist for Prostate Cancer: Final Analysis of the Equinoxe Study

2019 · Stéphane Droupy*, Marie-Hélène Colson, et al. · The Journal of Urology

PDF

Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin-releasing hormone (GnRH) agonist for prostate cancer: Final analysis of the EQUINOXE study

2019 · S. Droupy, M. Colson, et al. · European Urology Supplements

Impact de la cohésion relationnelle et de la sexualité sur la qualité de vie des patients traités par agoniste de l’hormone libérant la gonadotrophine (GnRH) pour un cancer de la prostate : analyse finale de l’étude EQUINOXE

2018 · S. Droupy, M.H. Colson, et al. · The French Journal of Urology

Impact émotionnel et affectif du cancer de la prostate chez 492 patients traités par agoniste de l’hormone libérant la gonadotrophine (gnrh) : perception du couple

2018 · M. Colson, A. Descazeaud, et al. · The French Journal of Urology

Works count: 30

Citation count: 16

H-index: 2

I10-index: